Study: US Medicare pricing policy may reshape global drug markets
Source Summary
A Lancet study models the impact of Medicare's new Most-Favored-Nation pricing policy, which ties U.S. drug prices to those in other high-income countries. For approximately three-quarters of medicines studied, the resulting Medicare savings would exceed four times the drug's annual sales in the reference country, potentially incentivizing manufacturers to raise prices or delay product launches globally.
Why it matters
The study demonstrates that Medicare's pricing policy creates substantial financial incentives for pharmaceutical manufacturers to alter their global pricing and launch strategies, potentially affecting drug availability and pricing in other countries.
